Topic 4 — How PRAME + HLA Enable TCR-T (and Why Timing Matters)

“Advancing Melanoma Care: Early Identification, Timely Action, and Next-Generation Therapy,” is an educational video series focusing on earlier identification of advanced melanoma, routine HLA-A*02:01 testing, and timely referral to IMA203 (anzu-cel) trial sites. In Topic 4, “How PRAME + HLA Enable TCR-T (and Why Timing Matters),” Alison Betof, MD, PhD, FASCO—Director, Melanoma Program, Mark and Mary Stevens Endowed Scholar in Melanoma, and Director, Solid Tumor Cellular Therapy at Stanford University School of Medicine—discusses how TCR-T therapy relies on two biological prerequisites — the presence of the PRAME antigen and the correct HLA type — and on the patient having sufficient immune fitness for their T cells to be engineered successfully. Topics in this brief educational video include PRAME as an important target in melanoma, how TCR-T binds PRAME peptide presented by HLA-A*02:01, and what engineered TCRs provide (i.e, increased affinity, improved specificity, and targeted melanoma cell killing). The fourth segment of the series concludes with a discussion of how T-cell fitness and how T-cell quality determines TCR-T success.